The company has received the Establishment Inspection Report and an approval letter from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection at its special economic zone (SEZ) oncology injectable manufacturing facility in SEZ1, Ahmedabad. The clearance relates to a new isolator injectable line and was disclosed in a filing dated 16 April, 2026. The inspection took place from fourth to 13th November, 2025 and resulted in documentation that the company said it had received. The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI. The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting. Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.